瑞替普酶治疗急性心肌梗死的有效性与安全性临床分析

Efficacy and safety of reteplase as therapy in the patients with acute myocardial infarction

目的探讨瑞替普酶（reteplase，rPA）静脉溶栓治疗急性心肌梗死（acutemyocardialinfarction，AMI）的疗效及安全性。方法选择74例发病〈12h的AMI患者作为观察组，采用rPA进行静脉溶栓，并回顾性分析138例应用阿替普酶（rt-PA）治疗的AMI患者作为对照。研究溶栓再通率、急性期病死率、不良事件发生率。结果观察组溶栓再通率高于rt—PA组（P〈0．05）；急性期病死率两者比较，差异无统计学差异（p〉0．05）；观察组出血并发症略高于对照组（P〈0．05）。结论rPA静脉溶栓治疗血管再通率高、安全、副作用少，并且给药方便。

Objective To evaluate the efficacy and safety of rPA for intravenous thrombolysis therapy in patients with acute myocardial infarction（AMI）. Methods 74 Patients were treated with intravenous rPA, a retrospective analysis of 138 patients treated by intravenous rt-PA was as control group. Then the clinical repatency rate, acute phase mortality, complications, aqkverse event incidence were observed. Results Thrombolytic recanalization rate of rPA group was higher than that of rt-PA （P〈0.05）, there was no statistically significant difference in acute mortality, while hemorrhage in rPA groups was slightly higher than that in rt-PA group （P〈0.05）. Conclusion The rPA has higher repatency rate, higher safety, fewer side effects, and convenient administration.